In light of recent data theft at retailers and other businesses, as well as amid fears of additional data breaches as the healthcare environment migrates to the digital world, Johns Hopkins information security experts have helped organize a conference to inform top executives about the growing risks of digital break-ins, how to reduce these risks, and how to manage the aftermath of a data breach.

An analysis of genetic biomarkers from Genetic Engineering & Biotechnology explains the differences between predictive and prognostic characteristics and provides a perspective on the current landscape of research and development for a number of key assays.

Myocardial perfusion imaging (MPI) with PET and F-18 flurpiridaz may reduce radiation dose while still providing comparable image quality to SPECT, the current standard, according to a study presented at the recent American Society of Nuclear Cardiology (ASNC) Annual Scientific Session held in Boston from Sept 18-21.

Lasers that can flip cells off and on and brain scanners that can be worn are just two projects receiving federal grants as a part of the $100 million BRAIN Initiative aimed to learn more about the inner-workings of the brain.

Lower amounts of a protein called progranulin in the brain have been shown to increase beta-amyloid formation and neuroinflammation. A gene therapy may be the key to reversing these markers of Alzheimer’s disease, Gladstone Institutes announced yesterday.

BioClinica, Inc., a leading provider of outsourced clinical trial services and eClinical Solutions, today announced that its Compass technology, a risk-based monitoring solution that improves overall quality in clinical trials, has won the inaugural Society for Clinical Data Management (SCDM) NextGen Technology Innovation (TIA) Award.

Following World Alzheimer's Day, a list of recent Alzheimer's studies, including brain PET research, was recently published by Examiner.com.

Acorda Therapeutics has made an agreement with Civitas Therapeutics to acquire the latter for $525 million. The purchase comes with global rights over a portfolio of drugs in development, including an inhalable drug called CVT-301, currently being validated for the treatment of Parkinson’s disease symptoms, Acorda announced Sept. 24.